# Rainbow Childrens Medicare share price today (Rainbow Childrens Medicare Ltd, NSE: RAINBOW)

> Rainbow Childrens Medicare share price today: ₹1,246.40 at the NSE close on 3 November 2026, down 9.0% in a year. Rainbow Childrens Medicare (NSE: RAINBOW) is worth ₹12,656 crore, trades at a P/E of 43.1 and has closed between ₹1,114.30 and ₹1,556.70 over the past 52 weeks. > Rainbow Childrens Medicare Ltd's earnings have grown faster than its share price. Earnings per share grew +14.3% in a year while the price moved −9.0%. RAINBOW · Hospitals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Growing steadily, from the last 12 quarters
- Price: ₹1,246.40 (−9.0% in a year)
- P/E: 43.1× (lower than 98% of the last 4.5 years)
- Revenue (Sep 2026): ₹548 Cr (+23.1% on a year ago)
- Profit (Sep 2026): ₹84.0 Cr (+10.5% on a year ago)
- Operating margin: 31.0% (−2.0 points on a year ago)
- ROCE: 17%, FY26
- ROIC: 15.1%, against a 12.0% cost of capital: +3.1 points

The main question: foreign institutions moved −10.5 percentage points over 8 quarters while the business went the other way. ## What is the Rainbow Childrens Medicare share price today? Rainbow Childrens Medicare Ltd's share price was ₹1,246.40 at the close on 3 November 2026. It has been falling for 1 week. That is 8.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,114 and ₹1,557, and at that close it sat 30% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 7 weeks running. Over the last 4.5 years the share price moved +173% while the NIFTY 500 moved +57%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Rainbow Childrens Medicare this quarter? Three changes stood out: foreign funds (FIIs) cut their stake for 7 quarters in a row, indian funds and insurers (DIIs) raised their stake for 9 quarters in a row and revenue up on a year earlier for 12 quarters in a row (every quarter we can compare). 1. Foreign funds (FIIs) cut their stake for 7 quarters in a row From 25.1% to 14.7% of the company by the September 2026 quarter. 2. Indian funds and insurers (DIIs) raised their stake for 9 quarters in a row From 13.8% to 23.3% of the company by the September 2026 quarter. 3. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹548 crore, +23.1% on a year earlier. ## What are Rainbow Childrens Medicare's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Rainbow Childrens Medicare reported revenue of ₹548 crore, up 23.1% from ₹445 crore a year earlier, and a profit of ₹84.0 crore, up 10.5% from ₹76.0 crore. ### Rainbow Childrens Medicare results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹548 crore | ₹445 crore | +23.1% |
| Profit | ₹84.0 crore | ₹76.0 crore | +10.5% |
| Earnings per share | ₹8.08 | ₹7.41 | +9.0% |
| Operating margin | 31.0% | 33.0% | −2.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 31 July 2026, about April to June 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Rainbow Childrens Medicare share price history? Rainbow Childrens Medicare closed at ₹1,246.40 on 3 November 2026, down 9.0% from ₹1,369.40 a year earlier (31 October 2025) and up 20.1% over three years. Its highest weekly close since May 2022 was ₹1,649.75 on 14 November 2024. ### Rainbow Childrens Medicare share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,169.60 | +6.6% |
| 1 month ago · 1 Oct 2026 | ₹1,279.80 | −2.6% |
| 6 months ago · 30 Apr 2026 | ₹1,252.30 | −0.5% |
| 1 year ago · 31 Oct 2025 | ₹1,369.40 | −9.0% |
| 3 years ago · 3 Nov 2023 | ₹1,037.55 | +20.1% |
| Earliest weekly close in our records · 13 May 2022 | ₹456.40 | +173.1% |
| Highest weekly close since May 2022 · 14 Nov 2024 | ₹1,649.75 | −24.4% |
| Lowest weekly close since May 2022 · 17 Jun 2022 | ₹426.60 | +192.2% |
| 52-week high (weekly close) · 7 Aug 2026 | ₹1,556.70 | −19.9% |
| 52-week low (weekly close) · 20 Mar 2026 | ₹1,114.30 | +11.9% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (241 weekly closes from 13 May 2022 to 3 November 2026.)

## What is the latest news on Rainbow Childrens Medicare? 3 Nov 2026: Rainbow Childrens Medicare closed at ₹1,246.40, up 6.6% on the week and down 2.6% on the month. Results for July to September 2026: Revenue up 23.1% and profit up 10.5% on a year earlier. ### Earlier

- 31 Jul 2026: Rainbow Childrens Medicare held its results call for April to June 2026. Management guided: Add 2,500 beds over 5 years to reach 5,000 network beds, with estimated capital spending around ₹2,200 crore; 1,200 beds are already in execution. - 21 Jul 2026: ex-date for a dividend of ₹3.50 a share. ## What dividend does Rainbow Childrens Medicare pay? Rainbow Childrens Medicare paid ₹3.50 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.28% at the ₹1,246.40 close on 3 November 2026. The last was a dividend of ₹3.50 a share, ex-date 21 July 2026. ### Rainbow Childrens Medicare dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 21 Jul 2026 | ₹3.50 | Dividend | same day |
| 27 Jun 2025 | ₹3 | Dividend | 28 Jun 2025 |
| 23 Jul 2024 | ₹3 | Dividend | same day |
| 22 Jun 2023 | ₹3 | Dividend | same day |
| 7 Sep 2022 | ₹2 | Dividend | 8 Sep 2022 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Rainbow Childrens Medicare Ltd paid out 13% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Rainbow Childrens Medicare management say on the latest results call? On the call for April to June 2026, held on 31 July 2026, Rainbow Childrens Medicare's management guided: Add 2,500 beds over 5 years to reach 5,000 network beds, with estimated capital spending around ₹2,200 crore; 1,200 beds are already in execution. > “Over the next 5 years, we plan to add 2,500 beds to expand our network capacity to 5,000 beds through estimated capex of around Rs 2,200 crore.”
> Dr. Ramesh Kancharla, on the call for April to June 2026

### What management guided

- Commissioning schedule: Indore in October to December 2026; Coimbatore and Gurgaon Sector 56 in October to December 2027; Gurgaon Sector 44 in April to June 2028; Pune 150-bed and Bengaluru Sarjapur facilities in FY29. - Malad's 100-bed brownfield hospital is expected to commence in April to June 2027; Nellore's 30-bed maternal block is expected within 6 months and Guntur's 50-bed facility in a couple of months. - Incremental beds are expected to be allocated approximately 30.0% to southern markets and 70.0% to new markets, including NCR, Central India and Mumbai. - July to September 2026 revenue growth is expected around 20.0%, with management stating it should not be less than 20.0%; the medium-term goal is 20.0% growth, implying revenue doubles in 4 years. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/47093-31-Jul-2026.pdf). (From the call for April to June 2026, 31 July 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Rainbow Childrens Medicare's next results? When Rainbow Childrens Medicare reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: July to September 2026 reported revenue growth to remain at least approximately 20.0%, consistent with management's extracted commitment. - What to check (from the call)
- July to September 2026 reported revenue growth to remain at least approximately 20.0%, consistent with management's extracted commitment. - Progress toward the FY27 operating margin range of 24.0%-25.0% pre-IND AS by year-end, despite continued start-up losses. - Electronic City to reach break-even within approximately 2-3 months, while the broader 18-month new-hospital break-even framework is tested across Bangalore. - Near-term expansion execution: Guntur's 50-bed facility within a couple of months and Nellore's 30-bed maternal block within 6 months, without an operating profit drain from the acquisitions. ## Which stock lists is Rainbow Childrens Medicare on? Rainbow Childrens Medicare is not on any of our India lists this week. ## Is Rainbow Childrens Medicare profitable? Rainbow Childrens Medicare Ltd earned ₹84.0 Cr of net profit in the Sep 2026 quarter, +10.5% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY26 profit was ₹282 Cr. Over 10 years profit has grown 32.4% a year on average. That is 15.3% of the quarter's revenue. The same quarter a year earlier earned ₹76.0 Cr. For the full year, FY26 profit was ₹282 Cr (+15.6% on the year before). Why profit moved: revenue changed +23.1% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +17.8% and revenue +23.1%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Rainbow Childrens Medicare make, and is it growing? Rainbow Childrens Medicare Ltd reported ₹548 Cr of revenue in the Sep 2026 quarter, +23.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 22.0% a year on average. The last full year, FY26, came in at ₹1,703 Cr. The last four reported quarters add to ₹1,923 Cr. FY26 revenue was ₹1,703 Cr, +12.3% on the year before. Recent pace: the last four quarters grew +23.1% on average, against 22.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +22.8%, against +16.2% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +16.8%, against +13.3% a year (accelerating). ## How much of every ₹100 of sales does Rainbow Childrens Medicare keep? Rainbow Childrens Medicare Ltd's operating margin was 31.0% in the Sep 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 13.0% and 34.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −2.4 percentage points on the year while gross margin changed +0.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Rainbow Childrens Medicare's profit turning into cash? Over the last 3 years, 153% of Rainbow Childrens Medicare Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹420 Cr of operating cash against ₹282 Cr of profit. After ₹560 Cr of spending on assets, free cash was −₹140 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 153% of profit came in as cash: the cash cycle got 57 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 3.2× depreciation over three years. The next section checks what that spending is building. ## Where does Rainbow Childrens Medicare's cash go? Rainbow Childrens Medicare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −73 days in FY26, up from −130 days in FY21. It spent ₹1,282 Cr on assets over the last 3 years. Customers take 22 days to pay, and stock sits for 67 days on average. At FY26 sales of ₹1,703 Cr, each day of that cycle ties up about ₹4.7 Cr, so roughly −₹341 Cr is tied up in the business at any time. FY26: customers took 22 days to pay and stock sat for 67 days, about 2.2 months of sales sitting as stock, for a full cycle of −73 days, longer than FY21's −130. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 67 days. Customers pay about 22 days after that. Suppliers are paid at 162 days. Together that makes the −73-day cycle. Spending on assets: ₹1,282 Cr over the last 3 years, against ₹401 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹79.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Rainbow Childrens Medicare's P/E ratio, and how does it compare with its own history? Rainbow Childrens Medicare Ltd's P/E is 43.1×, about the lowest it has ever been. Its usual P/E (the middle reading) is 53.5×, over 4.5 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +14.3% while the price moved −9.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +6.3% a year; about +10.3% a year came from earnings growth and about −4.0 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Rainbow Childrens Medicare business getting better or worse? Rainbow Childrens Medicare Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 18.7%. This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## How much does Rainbow Childrens Medicare earn on its capital? Rainbow Childrens Medicare Ltd earned a ROCE of 17% in FY26. That is up from a low of 11% in FY16. Its return on capital used (ROIC) is 3.1 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 16.6% net margin and 0.61× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 16.6% net margin × 0.61× asset turnover × 1.68× leverage (assets divided by equity) ≈ 17.0% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 15.1% − 12.0% = +3.1 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 15.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 17.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Rainbow Childrens Medicare have too much debt? Rainbow Childrens Medicare Ltd has total debt of ₹891 Cr against shareholder equity of ₹1,664 Cr as of Jun 2026, so its debt is 0.54× its equity. Year by year, that ratio went from 0.96 in FY22 to 0.54 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Rainbow Childrens Medicare shareholding pattern? Foreign institutions cut their stake in Rainbow Childrens Medicare Ltd by 10.5 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 14.7% of the company. Domestic institutions moved +9.4 points over the same period, to 23.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −10.5 points over 8 quarters, to 14.7%; Domestic institutions: +9.4 points over 8 quarters, to 23.3%; Promoters: +0.0 points over 8 quarters, to 49.8%. Why the owners changed: foreign institutions moved −10.5 points and domestic institutions +9.4 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Rainbow Childrens Medicare from balance-sheet trouble? For Rainbow Childrens Medicare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Rainbow Childrens Medicare rank in its industry? 50.3 out of 100, rank 11 of 20 in Hospitals, with 100% of the evidence available. Rainbow Childrens Medicare Ltd scores 50.3 out of 100 against the 20 companies it is compared with in Hospitals, ranking 11. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 17.5 + 20.1 + 9.3 + 3.4 = 50.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Rainbow Childrens Medicare compared with? Rainbow Childrens Medicare ranks 11 of 20 Hospitals companies on the 4-Factor Sector Score, with 50.3 out of 100. 1. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) KMCSHIL · breaking out · Sector-leading setup · 81% evidence 80.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 35.1% · Profit 100% · Operating margin change 6 points · 88% evidence Capital efficiency 23.1/25 · ROCE 26.2% · Operating margin 31% · 100% evidence Valuation 14.1/20 · P/E 43.4× · PEG 0.68 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 45.6% · 1 year 115.4% · 25% evidence · 5 of 5 weeks ahead Exact sum: 31 + 23.1 + 14.1 + 12.5 = 80.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) SAKAR · leader · Most evidence points up · 100% evidence 68.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.5% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 11.5/25 · ROCE 12.4% · Operating margin 28% · 100% evidence Valuation 11.1/20 · P/E 49× · PEG 1.05 · 100% evidence Relative strength 13.8/20 · Lead over its industry 41.8% · Lead over NIFTY 500 45.4% · 1 year 161.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.5 + 11.5 + 11.1 + 13.8 = 68.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Apollo Hospitals Enterprise Ltd](https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd) APOLLOHOSP · turning · Most evidence points up · 78% evidence 68.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 17.2% · Profit 33.2% · Operating margin change 1 points · 83% evidence Capital efficiency 15.2/25 · ROCE 17.4% · Operating margin 16% · 76% evidence Valuation 12.7/20 · P/E 57.7× · PEG n/a · 50% evidence Relative strength 16.6/20 · Lead over its industry 6.6% · Lead over NIFTY 500 11.2% · 1 year 10% · 100% evidence · 4 of 12 weeks ahead Exact sum: 24 + 15.2 + 12.7 + 16.6 = 68.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) DRAGARWQ · breaking out · Evidence leans up · 81% evidence 62.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 20.1% · Profit 31.6% · Operating margin change -2 points · 88% evidence Capital efficiency 17.4/25 · ROCE 17.2% · Operating margin 30% · 100% evidence Valuation 12.5/20 · P/E 33.7× · PEG 1.36 · 100% evidence Relative strength 11.6/20 · Lead over its industry n/a · Lead over NIFTY 500 9.2% · 1 year 0.8% · 25% evidence · 8 of 12 weeks ahead Exact sum: 21.1 + 17.4 + 12.5 + 11.6 = 62.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) KOVAI · breaking out · Evidence leans up · 96% evidence 61.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 15% · Profit 15.8% · Operating margin change 1 points · 88% evidence Capital efficiency 19.1/25 · ROCE 22.6% · Operating margin 29% · 100% evidence Valuation 8.9/20 · P/E 24.8× · PEG 2.01 · 100% evidence Relative strength 14.7/20 · Lead over its industry 1.9% · Lead over NIFTY 500 6.6% · 1 year -9.2% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.8 + 19.1 + 8.9 + 14.7 = 61.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [GPT Healthcare Ltd](https://www.sectoralpha.in/stocks/gpt-healthcare-ltd) GPTHEALTH · quiet · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.4/35 · Revenue 18% · Profit 0% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 19.9% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 23× · PEG 0.94 · 100% evidence Relative strength 9.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -2.1% · 1 year -10.7% · 25% evidence · 4 of 12 weeks ahead Exact sum: 15.4 + 18.2 + 18.5 + 9.1 = 61.2 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) YATHARTH · breaking out · Evidence leans up · 78% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 43.9% · Profit 22.5% · Operating margin change -2 points · 83% evidence Capital efficiency 12.4/25 · ROCE 12.9% · Operating margin 23% · 76% evidence Valuation 6.7/20 · P/E 49.3× · PEG n/a · 50% evidence Relative strength 19.1/20 · Lead over its industry 17.1% · Lead over NIFTY 500 21.6% · 1 year 16.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.4 + 12.4 + 6.7 + 19.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ARTEMISMED · leader · Evidence leans up · 100% evidence 56.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 14.7% · Profit 20% · Operating margin change 0 points · 100% evidence Capital efficiency 12.8/25 · ROCE 14.6% · Operating margin 18% · 100% evidence Valuation 8.0/20 · P/E 39.7× · PEG 2.44 · 100% evidence Relative strength 16.7/20 · Lead over its industry 8.4% · Lead over NIFTY 500 12.9% · 1 year 18.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 19.4 + 12.8 + 8 + 16.7 = 56.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) INDRAMEDCO · quiet · Evidence leans up · 85% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Revenue 10.8% · Profit 10.9% · Operating margin change 0 points · 100% evidence Capital efficiency 17.6/25 · ROCE 35.8% · Operating margin 19% · 100% evidence Valuation 13.2/20 · P/E 14.6× · PEG 1.47 · 100% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -49.6% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.3 + 17.6 + 13.2 + 7.7 = 51.8 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 10. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) MEDANTA · losing its lead · Evidence leans up · 96% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.5/35 · Revenue 21.3% · Profit 3.4% · Operating margin change -2 points · 88% evidence Capital efficiency 17.3/25 · ROCE 17.4% · Operating margin 22% · 100% evidence Valuation 5.5/20 · P/E 59.7× · PEG 9.11 · 100% evidence Relative strength 14.2/20 · Lead over its industry 3.7% · Lead over NIFTY 500 8.1% · 1 year -3.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.5 + 17.3 + 5.5 + 14.2 = 50.5 · What this means: Relative strength against the index is 8.1%, and revenue and profit growth are weak. 11. Rainbow Childrens Medicare Ltd this page RAINBOW · quiet · Evidence leans up · 100% evidence 50.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 22.8% · Profit 16.8% · Operating margin change -2 points · 100% evidence Capital efficiency 20.1/25 · ROCE 17.4% · Operating margin 31% · 100% evidence Valuation 9.3/20 · P/E 42.2× · PEG 4.32 · 100% evidence Relative strength 3.4/20 · Lead over its industry -7.2% · Lead over NIFTY 500 -3.1% · 1 year -11% · 100% evidence · 3 of 12 weeks ahead Exact sum: 17.5 + 20.1 + 9.3 + 3.4 = 50.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 12. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) MAXHEALTH · quiet · Evidence leans down · 85% evidence 48.7 out of 100 Growth Capital Valuation Relative
13. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) FORTIS · basing · Evidence leans down · 78% evidence 45.1 out of 100 Growth Capital Valuation Relative
14. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) SHALBY · quiet · Evidence leans down · 63% evidence 42.0 out of 100 Growth Capital Valuation Relative
15. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) NH · quiet · Evidence leans down · 78% evidence 40.8 out of 100 Growth Capital Valuation Relative
16. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ASTERDM · quiet · Evidence leans down · 96% evidence 35.2 out of 100 Growth Capital Valuation Relative
17. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) KIMS · quiet · Most evidence points down · 78% evidence 34.8 out of 100 Growth Capital Valuation Relative
18. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) JLHL · quiet · Most evidence points down · 100% evidence 33.0 out of 100 Growth Capital Valuation Relative
19. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) HCG · quiet · Most evidence points down · 71% evidence 31.1 out of 100 Growth Capital Valuation Relative
20. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) MANIPALHOS · Too little evidence to rank firmly · 38% evidence 42.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals](https://www.sectoralpha.in/sectors/hospitals), all 20 compared on one page. ## Which companies are close to Rainbow Childrens Medicare in size? Rainbow Childrens Medicare is the 9th largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Narayana Hrudayalaya, Global Health and Krishna Institute of Medical Sciences. Just below it: Yatharth Hospital & Trauma Care Services, Healthcare Global Enterprises and Jupiter Life Line Hospitals. ### Hospitals companies close in size

1. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) ₹35,154 crore
2. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) ₹34,156 crore
3. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) ₹29,476 crore
4. Rainbow Childrens Medicare Ltd ₹12,378 crore
5. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) ₹8,931 crore
6. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) ₹8,742 crore
7. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) ₹8,430 crore

[All 20 Hospitals companies, largest first](https://www.sectoralpha.in/sectors/hospitals#all-companies)

### Companies close in size in other industries

1. [CCL Products (India) Ltd](https://www.sectoralpha.in/stocks/ccl-products-indialtd) ₹12,445 crore · FMCG - Coffee
2. [Ventive Hospitality Ltd](https://www.sectoralpha.in/stocks/ventive-hospitality-ltd) ₹12,414 crore · Hotels
3. Rainbow Childrens Medicare Ltd ₹12,378 crore
4. [Crompton Greaves Consumer Electricals Ltd](https://www.sectoralpha.in/stocks/crompton-greaves-consumer-electricals-ltd) ₹12,334 crore · Consumer Electronics
5. [V-Guard Industries Ltd](https://www.sectoralpha.in/stocks/v-guard-industries-ltd) ₹12,247 crore · Capital Goods - Electric General

## What else do people ask about Rainbow Childrens Medicare? ### What is Rainbow Childrens Medicare's share price today? Rainbow Childrens Medicare Ltd's share price is ₹1,246.40, −9.0% over the past year. The whole company is worth ₹12,656 Cr on the market. In the last 52 weeks it traded between ₹1,114 to ₹1,557; today it is 30% of the way up from the low, 8.1% below its 200-day average (as of 3 November 2026). ### What were Rainbow Childrens Medicare's latest quarterly results? Rainbow Childrens Medicare Ltd reported revenue of ₹548 Cr and net profit of ₹84.0 Cr for the Sep 2026 quarter. Revenue rose 23.1% and profit rose 10.5% compared with a year earlier. Earnings per share were ₹8.08. The operating margin was 31.0%, 2.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Rainbow Childrens Medicare's market cap? Rainbow Childrens Medicare Ltd's market capitalisation is ₹12,656 Cr at a share price of ₹1,246.40. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### What is Rainbow Childrens Medicare's P/E ratio? Rainbow Childrens Medicare Ltd's P/E is 43.1×, higher than 2% of its own last 5 years. Its usual level (the middle reading) is 53.5×. This compares the price with the company's own past; it is not a view on what the shares are worth (as of 3 November 2026). ### How is Rainbow Childrens Medicare valued against its own history? Against its own history, Rainbow Childrens Medicare Ltd's valuation is low: its P/E of 43.1× has been lower only 2% of the time in 5 years (usual level 53.5×). This compares the price with the company's own past; it is not a view on what the shares are worth or where the price goes next (as of 3 November 2026). ### How is Rainbow Childrens Medicare performing? Rainbow Childrens Medicare Ltd's share price has been falling for 1 weeks. In its latest quarter, revenue rose 23.1% and profit rose 10.5% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 7 weeks running (as of 3 November 2026). ### Will Rainbow Childrens Medicare's share price go up? This page does not forecast Rainbow Childrens Medicare Ltd's share price. What it shows instead: the share price is ₹1,246.40, and it has been falling for 1 weeks. Its P/E of 43.1× is higher than 2% of its own last 5 years (as of 3 November 2026). ### Who owns Rainbow Childrens Medicare? Promoters own 49.8% of Rainbow Childrens Medicare Ltd, foreign institutions 14.7%, domestic institutions 23.3% and the public 11.8% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 10.5 percentage points over 8 quarters (as of 3 November 2026). ### Does Rainbow Childrens Medicare have too much debt? Rainbow Childrens Medicare Ltd has a moderate amount of debt: its debt is 0.54× its equity, and its operating profit is 7 times its interest bill. FY26 borrowings were ₹891 Cr against equity of ₹1,649 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Rainbow Childrens Medicare in its business cycle? Rainbow Childrens Medicare Ltd's FY26 operating margin was 32.0%, against a 13-year range of 13.0% to 34.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 31.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Rainbow Childrens Medicare story? The main question: foreign institutions moved −10.5 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Rainbow Childrens Medicare a stock worth studying right now? What the numbers show: Rainbow Childrens Medicare Ltd's earnings have grown faster than its share price. Earnings per share grew +14.3% in a year while the price moved −9.0%. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Rainbow Childrens Medicare share price forecast for 2026? What management itself guided: Add 2,500 beds over 5 years to reach 5,000 network beds, with estimated capital spending around ₹2,200 crore; 1,200 beds are already in execution. This is research, not advice. We’re not SEBI-registered.